NCT01667081View on ClinicalTrials.gov

Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017)

CompletedOBSERVATIONAL

Enrollment

2,438

Participants

Timeline

Start Date

October 17, 2012

Primary Completion Date

March 31, 2021

Study Completion Date

March 31, 2021

Conditions

Hepatitis C

Interventions

DRUG

Grazoprevir

Participants previously received study treatment with grazoprevir at the dose and frequency specified in the study protocol. Grazoprevir was not administered to participants in the course of this follow-up study.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01667081 - Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017) | Biotech Hunter | Biotech Hunter